Entera Bio

Company Overview

Snapshot

Founded in September 2009, Entera Bio operates with 11–50 employees. The company has raised a total of $333.9M across 8 funding rounds from 7 investors. Entera Bio went public on NASDAQ in July 2018, marking a significant milestone in its growth.

Business overview

Entera Bio is a biotechnology company focused on the oral delivery of large molecules and biologics. The company's proprietary technology enhances the absorption of these compounds in the gastrointestinal tract, addressing challenges related to oral drug delivery such as degradation by enzymes and poor absorption. Entera Bio is developing first-in-class, daily tablet protein and peptide replacement therapies, aiming to provide injection-free solutions for patients managing chronic diseases. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Drug Delivery, and Drugs Discovery & Development, serving patients in the healthcare and life sciences industries.

Strategic signal

In July 2026, Entera Bio secured $275M in a PIPE funding round. This substantial capital infusion signals strong investor confidence in the company's oral peptide programs, particularly its lead osteoporosis drug candidate, EB613, as it progresses towards a Phase 3 clinical trial. This funding is critical for advancing its pipeline and validating its oral delivery platform for large molecules.

Company Intelligence Q&A

When did Entera Bio go public?

Entera Bio went public on NASDAQ in July 2018.

What was a significant recent funding event for Entera Bio?

In July 2026, Entera Bio secured $275M in a PIPE funding round. This funding was critical for advancing its pipeline and validating its oral delivery platform for large molecules.

What was the focus of Entera Bio's collaboration with OPKO Biologics?

In September 2023, Entera Bio announced a collaboration with OPKO Biologics to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.

What progress has Entera Bio made with its EB613 osteoporosis treatment?

In October 2022, Entera Bio announced FDA agreement for a single Phase 3 clinical trial to support a New Drug Application for EB613 for the treatment of osteoporosis.

What was the outcome of the Q3 2024 financial results for Entera Bio?

In November 2024, Entera Bio reported its Q3 2024 financial results, including a Q3 loss, but topped revenue estimates.